Literature DB >> 35146579

Lymphoma pseudoprogression observed on [18F]FDG PET-CT scan 15 days after CAR-T infusion.

Dan Cohen1, Ofrat Beyar-Katz2,3, Einat Even-Sapir4,5, Chava Perry2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35146579     DOI： 10.1007/s00259-022-05722-y

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   10.057


× No keyword cloud information.
  5 in total

1.  Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma.

Authors:  Ivetta Danylesko; Roni Shouval; Noga Shem-Tov; Ronit Yerushalmi; Elad Jacoby; Michal J Besser; Avichai Shimoni; Tima Davidson; Katia Beider; Dror Mevorach; Shalev Fried; Arnon Nagler; Abraham Avigdor
Journal:  Bone Marrow Transplant       Date:  2020-12-03       Impact factor: 5.483

2.  Role of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Predicting the Adverse Effects of Chimeric Antigen Receptor T Cell Therapy in Patients with Non-Hodgkin Lymphoma.

Authors:  Jiasheng Wang; Yongxian Hu; Shuye Yang; Guoqin Wei; Xin Zhao; Wenjun Wu; Yanlei Zhang; Yafei Zhang; Donghe Chen; Zhao Wu; Lei Xiao; Alex Hongsheng Chang; He Huang; Kui Zhao
Journal:  Biol Blood Marrow Transplant       Date:  2019-02-12       Impact factor: 5.742

3.  Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.

Authors:  Laetitia Vercellino; Roberta Di Blasi; Salim Kanoun; Benoit Tessoulin; Cedric Rossi; Maud D'Aveni-Piney; Lucie Obéric; Caroline Bodet-Milin; Pierre Bories; Pierre Olivier; Ingrid Lafon; Alina Berriolo-Riedinger; Eugenio Galli; Sophie Bernard; Marie-Thérèse Rubio; Celine Bossard; Veronique Meignin; Pascal Merlet; Pierre Feugier; Steven Le Gouill; Loic Ysebaert; Olivier Casasnovas; Michel Meignan; Sylvie Chevret; Catherine Thieblemont
Journal:  Blood Adv       Date:  2020-11-24

4.  Novel patterns of response under immunotherapy.

Authors:  E Borcoman; Y Kanjanapan; S Champiat; S Kato; V Servois; R Kurzrock; S Goel; P Bedard; C Le Tourneau
Journal:  Ann Oncol       Date:  2019-03-01       Impact factor: 32.976

5.  [18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies.

Authors:  Dan Cohen; Efrat Luttwak; Ofrat Beyar-Katz; Shir Hazut Krauthammer; Yael Bar-On; Odelia Amit; Ronit Gold; Chava Perry; Irit Avivi; Ron Ram; Einat Even-Sapir
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-09-04       Impact factor: 9.236
  5 in total
  2 in total

1.  A multimodal imaging workflow for monitoring CAR T cell therapy against solid tumor from whole-body to single-cell level.

Authors:  Rita Pfeifer; Janina Henze; Katharina Wittich; Andre Gosselink; Ali Kinkhabwala; Felix Gremse; Cathrin Bleilevens; Kevin Bigott; Melanie Jungblut; Olaf Hardt; Frauke Alves; Wa'el Al Rawashdeh
Journal:  Theranostics       Date:  2022-06-13       Impact factor: 11.600

Review 2.  Metabolic Imaging in B-Cell Lymphomas during CAR-T Cell Therapy.

Authors:  Flavia Linguanti; Elisabetta Maria Abenavoli; Valentina Berti; Egesta Lopci
Journal:  Cancers (Basel)       Date:  2022-09-27       Impact factor: 6.575
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.